Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome

Alport Syndrome is a rare genetic kidney disease characterized by progressive fibrosis that leads to declining kidney function and often renal failure, requiring dialysis or transplantation from early adulthood. It can also cause hearing loss and eye abnormalities. No approved disease-modifying treatments exist. Despite being classified as a rare disease, it affects an estimated 360,000 people across the top 16 global markets, including around 60,000 in the US. Alport Syndrome is a rare genetic...

TORONTO, 09/12/2025 (informazione.news - comunicati stampa - salute e benessere)

Alport Syndrome is a rare genetic kidney disease characterized by progressive fibrosis that leads to declining kidney function and often renal failure, requiring dialysis or transplantation from early adulthood. It can also cause hearing loss and eye abnormalities. No approved disease-modifying treatments exist. Despite being classified as a rare disease, it affects an estimated 360,000 people across the top 16 global markets, including around 60,000 in the US.

Fibrocor is supported by the Alport Syndrome Foundation, a US-based, patient-led, independent non-profit organization dedicated to improving the lives of people living with Alport Syndrome through the services it provides. These include access to its patient registry, outreach activities, patient perspective input, and regulatory engagement.

About Fibrocor Therapeutics
Fibrocor Therapeutics is developing first-in-class therapies that target kidney diseases at their roots by blocking fibroblast activation and excessive collagen deposition. The company's lead focus is Alport Syndrome, a severe condition with no disease-modifying treatments, with the goal of delivering life-changing outcomes for patients who often face early dialysis or transplantation. Using a biomarker-driven approach and human biopsy–derived targets, Fibrocor is advancing a deliberate, translatable clinical strategy and aims to seek accelerated approval for its lead program in 2029. Its fibrosis-targeting platform has broad potential across multiple kidney diseases and other organs. Fibrocor is powered by a seasoned leadership team, including CEO William Newsome, scientific leader Piet Wigerinck, and clinical expert Paul Ford, who have decades of experience in fibrosis biology, drug development, and clinical strategy. Leveraging patient-derived kidney tissue, Fibrocor is also advancing programs in ADPKD and transplant-related fibrosis, identifying precision targets to slow disease progression and preserve long-term organ health.

View original content:https://www.prnewswire.co.uk/news-releases/fibrocor-therapeutics-appoints-world-leading-nephrologists-to-clinical-advisory-board-with-a-focus-on-its-lead-indication-alport-syndrome-302635662.html